American journal of preventive medicine · 2025
Prevalence of Tobacco Use in Adults With Chronic Pain: Results From the National Health Interview Survey 2014-2023.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lazzari Julianna L, Rubenstein Dana, Powers Jessica M, Keefe Francis J, McClernon F Joseph, Pacek Lauren R, Sweitzer Maggie M
Аннотация
INTRODUCTION: Chronic pain is linked to elevated tobacco use, but long-term trends in combustible smoking and E-cigarette use in this group remain unclear. Understanding these trajectories is vital for designing effective public health interventions. This study examined national trends in exclusive cigarette smoking, exclusive E-cigarette use, and dual use (2014-2023) among U.S. adults with and without chronic pain.
METHODS: This was a serial cross-sectional analysis using 2014-2023 (excluding 2022) National Health Interview Survey data from 195,632 U.S. adults. Chronic pain (yes/no) was defined by self-reported pain frequency (past 3 months): every day or most days versus some days or never. Primary outcomes were exclusive cigarette smoking, exclusive E-cigarette use, and dual use prevalence by pain status and year, assessed through logistic regression. Secondary analyses examined pain frequency (continuous) and high-impact chronic pain (yes/no). Analyses were conducted in 2025.
RESULTS: Exclusive cigarette smoking prevalence was significantly higher and declined more slowly among individuals with chronic pain (17.7% in 2014 and 13.1% in 2023) than among those without (12.5% in 2014 and 7.5% in 2023; p<0.001). Adjusting for age, sex/gender, and race/ethnicity, both exclusive E-cigarette use and dual use prevalence were higher in the chronic pain group across all years. Exclusive E-cigarette use increased at similar rates among individuals with (1.4% in 2014 and 5.6% in 2023) and without (1.2% in 2014 and 4.5% in 2023; ps<0.001) chronic pain; dual use prevalence declined at similar rates among individuals with (4.6% in 2014 and 2.7% in 2023) and without (2.3% in 2014 and 1.5% in 2023) chronic pain.
CONCLUSIONS: Although U.S. exclusive cigarette smoking prevalence has decreased, individuals with chronic pain remain disproportionately impacted, emphasizing the need for targeted tobacco interventions.
METHODS: This was a serial cross-sectional analysis using 2014-2023 (excluding 2022) National Health Interview Survey data from 195,632 U.S. adults. Chronic pain (yes/no) was defined by self-reported pain frequency (past 3 months): every day or most days versus some days or never. Primary outcomes were exclusive cigarette smoking, exclusive E-cigarette use, and dual use prevalence by pain status and year, assessed through logistic regression. Secondary analyses examined pain frequency (continuous) and high-impact chronic pain (yes/no). Analyses were conducted in 2025.
RESULTS: Exclusive cigarette smoking prevalence was significantly higher and declined more slowly among individuals with chronic pain (17.7% in 2014 and 13.1% in 2023) than among those without (12.5% in 2014 and 7.5% in 2023; p<0.001). Adjusting for age, sex/gender, and race/ethnicity, both exclusive E-cigarette use and dual use prevalence were higher in the chronic pain group across all years. Exclusive E-cigarette use increased at similar rates among individuals with (1.4% in 2014 and 5.6% in 2023) and without (1.2% in 2014 and 4.5% in 2023; ps<0.001) chronic pain; dual use prevalence declined at similar rates among individuals with (4.6% in 2014 and 2.7% in 2023) and without (2.3% in 2014 and 1.5% in 2023) chronic pain.
CONCLUSIONS: Although U.S. exclusive cigarette smoking prevalence has decreased, individuals with chronic pain remain disproportionately impacted, emphasizing the need for targeted tobacco interventions.